ijms-logo

Journal Browser

Journal Browser

Rare Skin Cancer: From Pathophysiology to Novel Therapeutic Strategies

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Oncology".

Deadline for manuscript submissions: closed (20 November 2024) | Viewed by 2017

Special Issue Editor


E-Mail Website
Guest Editor
Department of Dermatology, Università degli Studi di Roma “Tor Vergata”, 00133 Rome, Italy
Interests: skin disease; melanoma; cutaneous lymphoma; basal cell carcinoma
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Skin cancer is one of the most widespread cancers, with a significant global health effect. Some rare skin cancers include rare epithelial tumors such as Merkel cell carcinoma, adnexal tumors, advanced basal cell carcinoma, rare melanocytic proliferations such as melanocytomas, and atypical Spitz tumors, lymphoid neoplasms (T- and B-cell primary cutaneous lymphoproliferations), and several mesenchymal proliferations such as Kaposi’s sarcoma, dermatofibrosarcoma protuberans, angiosarcoma or pleomorphic dermal sarcoma, which may cause profound mortality or morbidity among affected patients.

Despite the availability of various improved approaches for detecting and treating skin cancer, it continues to be the leading cause of death throughout society. This Special Issue will focus on pathological and targeted facets, biomarkers and molecular markers, immunotherapy, and clinical updates of investigational drugs associated with rare skin cancers.

Dr. Cosimo Di Raimondo
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Merkel cell carcinoma
  • Kaposi’s sarcoma
  • melanocytoma
  • Spitz tumor
  • adnexal carcinoma
  • advanced basal cell carcinoma
  • skin sarcoma

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

14 pages, 551 KiB  
Review
Blastic Plasmacytoid Dendritic Cell Neoplasm, from a Dermatological Point of View
by Cosimo Di Raimondo, Flavia Lozzi, Pier Paolo Di Domenico, Claudia Paganini, Elena Campione, Marco Galluzzo and Luca Bianchi
Int. J. Mol. Sci. 2024, 25(13), 7099; https://doi.org/10.3390/ijms25137099 - 28 Jun 2024
Cited by 2 | Viewed by 1703
Abstract
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is an aggressive hematological malignancy derived from the precursors of plasmacytoid dendritic cells. Although disease awareness has increased over time, BPDCN represents a rare disease with an aggressive clinical course and a dismal prognosis. Due to the [...] Read more.
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is an aggressive hematological malignancy derived from the precursors of plasmacytoid dendritic cells. Although disease awareness has increased over time, BPDCN represents a rare disease with an aggressive clinical course and a dismal prognosis. Due to the overlap in clinical and histological features with a large spectrum of inflammatory and neoplastic diseases, BPDCN is difficult to diagnose. Furthermore, given the rarity of the disease, treatment options for BPDCN are limited, sometimes changing by practitioner and hospitals. Treatment options range from conventional chemotherapy to the recently approved biologic agent tagraxofusp and stem cell transplantation. Therefore, a multidisciplinary approach with coordination among dermatologists, pathologists, and hematologists is ultimately imperative to reach the correct diagnosis and management of BPDCN. Full article
Show Figures

Figure 1

Back to TopTop